SCHEMBL892240

SCHEMBL892240

COc1ccc(-c2cc(C(=O)O)no2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 1.00
ALDH1A1 P00352 4/20 1.00
MAPT P10636 3/20 1.00
RECQL P46063 1/20 1.00
RAB9A P51151 8/20 0.68
NPC1 O15118 7/20 0.68
SMN1; SMN2 Q16637 4/20 0.68
TP53 P04637 3/20 0.68
CDH1 P12830 1/20 0.67
CTNNB1 P35222 1/20 0.67
TCF7L2 Q9NQB0 1/20 0.67
PTPN1 P18031 1/20 0.64
HSD17B10 Q99714 2/20 0.64
MAPK1 P28482 1/20 0.64
STAT1 P42224 1/20 0.64
HDAC3 O15379 1/20 0.60
HDAC4 P56524 1/20 0.60
HDAC1 Q13547 1/20 0.60
HDAC7 Q8WUI4 1/20 0.60
HDAC2 Q92769 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20507141 0.86 HPGD (0.75) HPGDALDH1A1MAPTRECQLRAB9A
SCHEMBL1179647 0.83 ALDH1A1 (1.00) HPGDALDH1A1MAPTRECQLRAB9A
SCHEMBL892878 0.81 ALDH1A1 (0.72) HPGDALDH1A1MAPTRECQLRAB9A
SCHEMBL17731967 0.81 MAPK1 (0.76) HPGDALDH1A1MAPTRECQLRAB9A
SCHEMBL15468398 0.81 MAPT (0.68) HPGDALDH1A1MAPTRECQLRAB9A
SCHEMBL12171504 0.81 NPC1 (0.72) HPGDALDH1A1MAPTRECQLRAB9A
SCHEMBL12171880 0.81 NPC1 (0.72) HPGDALDH1A1MAPTRECQLRAB9A
SCHEMBL20149361 0.80 CDH1 (1.00) HPGDALDH1A1MAPTRECQLRAB9A
SCHEMBL11902926 0.80 ALDH1A1 (0.67) HPGDALDH1A1MAPTRECQLRAB9A
SCHEMBL72786 0.80 ALDH1A1 (1.00) HPGDALDH1A1MAPTRECQLRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180273906-A1 MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS IPS HEART 2018-09-27 US claimed
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP claimed
EP-2170876-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF RESTENOSIS COMPRISING ISOXAZOLE DERIVATIVES SK HOLDINGS CO LTD (KR) 2011-12-28 EP claimed
US-20110028506-A1 Pharmaceutical Composition For Preventintion And Treatment Of Restenosis Comprising Isoxazole Derivatives SK BIOPHARMACEUTICALS CO., LTD. (KR) 2011-02-03 US claimed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US claimed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP claimed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO claimed
US-20250248990-A1 QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE NEURODON CORPORATION 2025-08-07 US disclosed
CN-115716822-B Application of benzimidazolyl isoxazoles in preparation of medicines related to multiple myeloma 徐州医科大学 2025-05-16 CN disclosed
US-12144806-B2 Quinolines that modulate SERCA and their use for treating disease NEURODON CORPORATION (US) 2024-11-19 US disclosed
US-20240277694-A1 QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE NEURODON CORPORATION 2024-08-22 US disclosed
US-12043602-B2 Fendiline derivatives THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-07-23 US disclosed
US-11992487-B2 Quinolines that modulate SERCA and their use for treating disease NEURODON CORPORATION (US) 2024-05-28 US disclosed
EP-2170876-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF RESTENOSIS COMPRISING ISOXAZOLE DERIVATIVES SK HOLDINGS CO LTD (KR) 2011-12-28 EP disclosed
WO-2010142801-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2010-12-16 WO disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed
US-20040110802-A1 Antibacterial benzoic acid derivatives PHARMACIA & UPJOHN COMPANY 2004-06-10 US disclosed
WO-2004018428-A1 ANTIBACTERIAL BENZOIC ACID DERIVATIVES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11992487-B2 Quinolines that modulate SERCA and their use for treating disease ATP2A1, ATP2A3, ATP2A2 HPGD 1001/4885ALDH1A1 1661/4885MAPT 1228/4885
US-20180273906-A1 MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS EXOSC9, EXOSC5, EXOSC4 HPGD 4358/4885ALDH1A1 493/4885MAPT 2473/4885
US-20110028506-A1 Pharmaceutical Composition For Preventintion And Treatment Of Restenosis Comprising Isoxazole Derivatives PTGIR, GPR119, PTGIS HPGD 362/4885ALDH1A1 957/4885MAPT 4662/4885
US-12144806-B2 Quinolines that modulate SERCA and their use for treating disease ATP2A1, ATP2A3, ATP2A2 HPGD 1001/4885ALDH1A1 1661/4885MAPT 1228/4885
US-20250248990-A1 QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE ATP2A1, ATP2A3, ATP2A2 HPGD 1001/4885ALDH1A1 1661/4885MAPT 1228/4885
US-12043602-B2 Fendiline derivatives CYP11B2, CYP3A7, CYP4F2 HPGD 946/4885ALDH1A1 292/4885MAPT 2791/4885
US-20240277694-A1 QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE ATP2A1, ATP2A3, ATP2A2 HPGD 1001/4885ALDH1A1 1661/4885MAPT 1228/4885
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 HPGD 732/4885ALDH1A1 706/4885MAPT 2497/4885
US-20040110802-A1 Antibacterial benzoic acid derivatives GABRD, GABBR1, GABRA1 HPGD 1657/4885ALDH1A1 170/4885MAPT 4759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.